美国心衰指南重磅更新！新型药物维利西呱崭露头角！

In April 2022, the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Failure Society of America (HFSA) jointly issued the "2022 AHA/ACC/HFSA Heart Failure Management Guidelines." The guideline has many updated highlights. It not only redefines the stages and classifications of heart failure, but also comprehensively updates management strategies and treatment plans, and fully affirms the therapeutic status of a variety of new drugs, which have also been included in the guidelines, adding new forces to the treatment of heart failure (HFrEF) patients.

Approximately 64.3 million people worldwide suffer from heart failure (HF), and the quality of life and prognosis of patients are poor. 87% of patients with heart failure suffer from three or more chronic comorbidities, and 50% of patients will die within 5 years after being diagnosed with heart failure. The American Heart Association (AHA) divides heart failure according to left ventricular ejection fraction (LVEF) into heart failure with reduced ejection fraction (HFrEF, LVEF<40%), heart failure with preserved ejection fraction (HFpEF, LVEF≥50%), and heart failure with intermediate ejection fraction (HFm-rEF, LVEF 40% 49%).

Vericiguat is the first soluble guanylate cyclase (sGC) agonist that has achieved positive results in the treatment of heart failure targeting the NO-sGC-eGMP pathway. It has good pharmacokinetic characteristics, low risk of drug interaction, high safety, and is suitable for combined drug treatment of patients with heart failure with multiple comorbidities. On January 19, 2021, Veliciguat was approved by the U.S. Food and Drug Administration (FDA) to reduce cardiovascular death in adult patients with symptomatic chronic heart failure with LVEF <45% who are hospitalized for heart failure or require outpatient intravenous diuretic treatment. and the risk of hospitalization for heart failure. Veciguat's marketing application in China has been officially included in priority review as "clinically urgently needed shortage drugs, innovative drugs and improved new drugs for the prevention and treatment of major infectious diseases, rare diseases and other diseases", providing a new treatment option for patients with worsening chronic heart failure.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.